Patents by Inventor John Isidro Trujillo

John Isidro Trujillo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Benzimidazole Derivatives and Their Use As Inhibitors of ITK For The Treatment of Skin Disease
    Publication number: 20240132477
    Abstract: The invention relates to benzimidazoles of Formula (I) and pharmaceutically acceptable salts thereof, wherein R1 to R6 are as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The benzimidazoles of Formula (I) are ITK inhibitors and are therefore potentially useful in the treatment of a wide range of disorders including, atopic dermatitis.
    Type: Application
    Filed: December 13, 2021
    Publication date: April 25, 2024
    Applicant: Pfizer Inc.
    Inventors: Scott William Bagley, Agustin Casimiro Garcia, Jennifer Elizabeth Davoren, Rajiah Aldrin Denny, Brian Stephen Gerstenberger, Frank Eldridge Lovering, Mihir Dineshkumar Parikh, Joseph Walter Strohbach, John Isidro Trujillo
  • Pyrido[2,3-D]Imidazole Derivatives and Their Use As Inhibitors of ITK for the Treatment of Skin Disease
    Publication number: 20240124439
    Abstract: The invention relates to imidazopyridines of Formula (I) and pharmaceutically acceptable salts thereof, wherein R0 to R5 are as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The benzimidazoles of Formula (I) are ITK inhibitors and are therefore potentially useful in the treatment of a wide range of disorders including, atopic dermatitis.
    Type: Application
    Filed: December 13, 2021
    Publication date: April 18, 2024
    Applicant: Pfizer Inc.
    Inventors: Scott William Bagley, Agustin Casimiro-Garcia, Jennifer Elizabeth Davoren, Rajiah Aldrin Denny, Brian Stephen Gerstenberger, Katherine Lin Lee, Frank Eldridge Lovering, Mihir Dineshkumar Parikh, Joseph Walter Strohbach, John Isidro Trujillo
  • Benzimidazole Derivative Compounds and Uses Thereof
    Publication number: 20230280220
    Abstract: The invention relates to benzimidazoles of Formula (1) and pharmaceutically acceptable salts thereof, wherein R1 to R6 are as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The benzimidazoles of Formula (1) are ITK inhibitors and are therefore potentially useful in the treatment of a wide range of disorders including, atopic dermatitis.
    Type: Application
    Filed: April 17, 2023
    Publication date: September 7, 2023
    Applicant: Pfizer Inc.
    Inventors: Scott William Bagley, Agustin Casimiro Garcia, Xiayun Cheng, Jennifer Elizabeth Davoren, Rajiah Aldrin Denny, Brian Stephen Gerstenberger, Frank Eldridge Lovering, Mihir Dineshkumar Parikh, Joseph Walter Strohbach, John Isidro Trujillo
  • N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as CCR6 inhibitors
    Patent number: 11708360
    Abstract: The present invention relates to N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamide compounds of Formulae (IA and 1B) or a pharmaceutically acceptable salt or hydrate thereof, that inhibit CC chemokine receptor 6 (CCR6), pharmaceutical compositions containing these compounds, and the use of these compounds for treating or preventing diseases, conditions, or disorders ameliorated by inhibition of CCR6.
    Type: Grant
    Filed: March 5, 2021
    Date of Patent: July 25, 2023
    Assignee: Pfizer Inc.
    Inventors: Brian Stephen Gerstenberger, Andrew Christopher Flick, Daniel Wei-Shung Kung, Vincent Michael Lombardo, James John Mousseau, Philippe Marcel Nuhant, Ralph Pelton Robinson, Jr., Daniel Copley Schmitt, Mark Edward Schnute, Atli Thorarensen, John Isidro Trujillo, Rayomand Jal Unwalla, Huixian Wu
  • Benzimidazole derivative compounds and uses thereof
    Patent number: 11661419
    Abstract: The invention relates to benzimidazoles of Formula (I) and pharmaceutically acceptable salts thereof, wherein R1 to R6 are as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The benzimidazoles of Formula (I) are ITK inhibitors and are therefore potentially useful in the treatment of a wide range of disorders including, atopic dermatitis.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: May 30, 2023
    Assignee: Pfizer Inc.
    Inventors: Scott William Bagley, Agustin Casimiro-Garcia, Xiayun Cheng, Jennifer Elizabeth Davoren, Rajiah Aldrin Denny, Brian Stephen Gerstenberger, Frank Eldridge Lovering, Mihir Dineshkumar Parikh, Joseph Walter Strohbach, John Isidro Trujillo
  • N-SUBSTITUTED-DIOXOCYCLOBUTENYLAMINO-3-HYDROXY-PICOLINAMIDES USEFUL AS CCR6 INHIBITORS
    Publication number: 20210206757
    Abstract: The present invention relates to N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamide compounds of Formulae (IA and 1B) or a pharmaceutically acceptable salt or hydrate thereof, that inhibit CC chemokine receptor 6 (CCR6), pharmaceutical compositions containing these compounds, and the use of these compounds for treating or preventing diseases, conditions, or disorders ameliorated by inhibition of CCR6.
    Type: Application
    Filed: March 5, 2021
    Publication date: July 8, 2021
    Applicant: Pfizer Inc.
    Inventors: Brian Stephen Gerstenberger, Andrew Christopher Flick, Daniel Wei-Shung Kung, Vincent Michael Lombardo, James John Mousseau, Philippe Marcel Nuhant, Ralph Pelton Robinson, JR., Daniel Copley Schmitt, Mark Edward Schnute, Atli Thorarensen, John Isidro Trujillo, Rayomand Jal Unwalla, Huixian Wu
  • Chemical Compounds
    Publication number: 20210188829
    Abstract: The invention relates to benzimidazoles of Formula (I) and pharmaceutically acceptable salts thereof, wherein R1 to R6 are as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The benzimidazoles of Formula (I) are ITK inhibitors and are therefore potentially useful in the treatment of a wide range of disorders including, atopic dermatitis.
    Type: Application
    Filed: December 18, 2020
    Publication date: June 24, 2021
    Applicant: Pfizer Inc.
    Inventors: Scott William Bagley, Agustin Casimiro-Garcia, Xiayun Cheng, Jennifer Elizabeth Davoren, Rajiah Aldrin Denny, Brian Stephen Gerstenberger, Frank Eldridge Lovering, Mihir Dineshkumar Parikh, Joseph Walter Strohbach, John Isidro Trujillo
  • N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as CCR6 inhibitors
    Patent number: 10975065
    Abstract: The present invention relates to N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamide compounds of Formulae (IA and 1B) or a pharmaceutically acceptable salt or hydrate thereof, that inhibit CC chemokine receptor 6 (CCR6), pharmaceutical compositions containing these compounds, and the use of these compounds for treating or preventing diseases, conditions, or disorders ameliorated by inhibition of CCR6.
    Type: Grant
    Filed: September 20, 2019
    Date of Patent: April 13, 2021
    Assignee: Pfizer Inc.
    Inventors: Brian Stephen Gerstenberger, Andrew Christopher Flick, Vincent Michael Lombardo, James John Mousseau, Philippe Marcel Nuhant, Ralph Pelton Robinson, Jr., Mark Edward Schnute, Daniel Wei-Shung Kung, Daniel Copley Schmitt, Atli Thorarensen, John Isidro Trujillo, Rayomand Jal Unwalla, Huixian Wu
  • N-SUBSTITUTED-DIOXOCYCLOBUTENYLAMINO-3-HYDROXY-PICOLINAMIDES USEFUL AS CCR6 INHIBITORS
    Publication number: 20200095239
    Abstract: The present invention relates to N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamide compounds of Formulae (IA and 1B) or a pharmaceutically acceptable salt or hydrate thereof, that inhibit CC chemokine receptor 6 (CCR6), pharmaceutical compositions containing these compounds, and the use of these compounds for treating or preventing diseases, conditions, or disorders ameliorated by inhibition of CCR6.
    Type: Application
    Filed: September 20, 2019
    Publication date: March 26, 2020
    Applicant: Pfizer Inc.
    Inventors: Brian Stephen Gerstenberger, Andrew Christopher Flick, Vincent Michael Lombardo, James John Mousseau, Philippe Marcel Nuhant, Ralph Pelton Robinson, JR., Mark Edward Schnute, Daniel Wei-Shung Kung, Daniel Copley Schmitt, Atli Thorarensen, John Isidro Trujillo, Rayomand Jal Unwalla, Huixian Wu